Cassava Sciences
Cassava Sciences
SAVA
NASDAQ
2.79
USD
0.00%
About
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation.
It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia.
SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.4M |
| Three Month Average Volume | 69.1M |
| High Low | |
| Fifty-Two Week High | 42.2 USD |
| Fifty-Two Week Low | 8.79 USD |
| Fifty-Two Week High Date | 05 Aug 2024 |
| Fifty-Two Week Low Date | 28 Jun 2024 |
| Price and Volume | |
| Current Price | 28.71 USD |
| Beta | -1 |
| Relative Price Change | |
| Four Week Relative Price Change | -6.64% |
| Thirteen Week Relative Price Change | 21.76% |
| Twenty-Six Week Relative Price Change | 13.53% |
| Fifty-Two Week Relative Price Change | 9.26% |
| Year-to-Date Relative Price Change | 7.70% |
| Price Change | |
| One Day Price Change | 0.70% |
| Thirteen Week Price Change | 30.32% |
| Twenty-Six Week Price Change | 24.83% |
| Five Day Price Change | -7.24% |
| Fifty-Two Week Price Change | 36.91% |
| Year-to-Date Price Change | 27.54% |
| Month-to-Date Price Change | 29.21% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.25469 USD |
| Book Value Per Share (Most Recent Quarter) | 3.93891 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.25052 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.9372 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.9947 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.31844 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.40544 USD |
| Normalized (Last Fiscal Year) | -2.31844 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.31844 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.3909 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.31844 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.40544 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.86801 USD |
| Cash Per Share (Most Recent Quarter) | 4.32071 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.28196 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.32117 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.97837 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 23.35% |
| Tangible Book Value (5 Year) | 47.55% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 121.11% |
| EPS Change (Trailing Twelve Months) | 81.47% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 10 |
| Price to Tangible Book (Most Recent Quarter) | 7 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -207,291,000 |
| Net Debt (Last Fiscal Year) | -121,136,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 9 |
| Price to Book (Most Recent Quarter) | 7 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -82,439,000 |
| Free Cash Flow (Trailing Twelve Months) | -86,306,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -50.31% |
| Return on Assets (Trailing Twelve Months) | -6.97% |
| Return on Assets (5 Year) | -30.74% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -53.27% |
| Return on Equity (Trailing Twelve Months) | -8.35% |
| Return on Equity (5 Year) | -32.15% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -53.23% |
| Return on Investment (Trailing Twelve Months) | -8.35% |
| Return on Investment (5 Year) | -32.12% |